There are no formal human clinical trials supporting the safety or efficacy of this specific combination
La tasa de abandono por efectos adversos es baja: 7% para retatrutida y 6% para Mounjaro
Retatrutide may, in time, receive regulatory approval and become a valuable addition to the weight management toolkit
Some individuals do tolerate faster titration, but this should be assessed and supervised by your clinician rather than self-managed
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
Drucker et ses collgues Jol Habener et Jens Juul Holst
